Kornimate/medical-research-clean huggingface dataset:
randomized trial of five or two mri-guided adaptive radiotherapy treatments for prostate cancer

Conditions: Prostate Cancer

Summary: the study is a randomized study that compares 5 radiation therapy treatments to 2 radiation therapy treatments in men with low or intermediate-risk prostate cancer.

this study is a randomized non-inferiority trial comparing 5 to 2 radiotherapy treatments using an mri linear accelerator for men with low or intermediate-risk prostate cancer electing for definitive radiotherapy.

Eligibility criteria:
inclusion criteria: * men aged \>=18 with histologically confirmed low or intermediate risk prostate cancer per nccn guidelines. * ecog 0 - 1 * ipss \< 18 * ability to receive mri-guided radiotherapy. * ability to complete the expanded prostate cancer index composite (epic) questionnaire. * patients with a prior or concurrent disease whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. note: any patient with a cancer (other than keratinocyte carcinoma or carcinoma in situ or low-grade non-muscle invasive bladder cancer) who has been disease-free for less than 3 years must contact the principal investigator. exclusion criteria: * prior history of receiving pelvic radiotherapy. * patient with history of inflammatory bowel disease. * mri prostate volume \> 80 cc * mri stage \> t3a * unilateral or bilateral hip replacements. * history of bladder neck or urethral stricture. * turp \< 8 weeks prior to radiotherapy * metastatic (pelvic nodal or distant) disease on ct, bone, fluciclovine, and/or psma pet scan

Keywords: low or intermediate risk prostate cancer definitive radiotherapy mri linear accelerator
taketina in the treatment of depression: a pilot study.

Conditions: Major Depressive Disorder

Summary: the goal of this clinical study's to analyse the impact of taketina music therapy in depressed patients. the main question\[s\] it aims to answer are: . can taketina result in a significant pre-to-post intervention decline of depression severity 2. can taketina result in a significantly lower post-intervention depression severity in the t1/t2 group than in the w1/w2 group. participants will * be randomly assigned to the two groups, intervention vs. waitlist * receive either an eight week taketina music therapy or waitlist * be analysed using questionaires, blood taking, cortisol saliva analysis, measured heart rate variability researchers will compare a waitlist to see if taketina is superior to waitlist

one third of the depressed patients do not respond adequately to conventional treatment. this seems to be associated with increased production of proinflammatory cytokines such as tnf-a and il-1, as well as dysregulation of cortisol levels. this project aims to investigate investigate the effectiveness of taketina music therapy in the treatment of patients with clinical diagnosis of moderate to severe depression investigate the physiological and pathophysiological effects of taketina using novel blood based biomarkers of depression, especially ldl cholesterol as well as on immune system function in order to establish immune system based biomarkers for better diagnosis and therapy monitoring of major depressive disorder.

Eligibility criteria:
inclusion criteria: major depressive disorder ability to walk, speak, and clap exclusion criteria: * psychotic symptoms * acute suicidality * prior intolerance to body therapeutic methods
neural mechanisms in asthma

Conditions: Asthma

Summary: asthma is a chronic disease that affects nearly 13% of adults in the u.s., causing substantial impairment that is reflected in the tens of millions of missed days of work, and doctors' and emergency room visits it leads to annually. those who have asthma are twice as likely to develop depression and anxiety, which are associated with more frequent and severe asthma symptoms, especially in those under chronic stress. the project proposed here seeks to understand the role of the brain in these associations and to evaluate the neural mechanisms through which a safe, low-cost intervention, that influences the function of body via the mind, may diminish the expression of asthma symptoms.


Eligibility criteria:
inclusion criteria: * asthmatics: * physician diagnosed asthma with previous use of asthma medication * controls: * negative skin-prick test to cat dander or house dust mite and have no history of asthma * chronic stress: * score 3 or above on any subscale of the ucla (university of california los angeles) chronic stress interview no chronic stress: score 1.5 or below on all subscales of the ucla chronic stress interview exclusion criteria: * individuals with severe asthma, or those whom currently require the use of corticosteroids * individuals with significant medical problems * individuals who smoke cigarettes * individuals a previous adverse reaction to corticosteroids, a recent (\< 1 month) viral illness, a history of severe asthma or anaphylaxis. * breastfeeding women or women who are, suspect they might be or are trying to become pregnant
eko sensora: detecting clinically significant murmurs

Conditions: Heart Murmurs

Summary: the eko artificial intelligence (ai) has primarily been evaluated in the primary care setting. the digital stethoscope records a phonocardiogram of heart sounds of the patient and uses machine learning artificial intelligence to identify if there are abnormalities present (eko health, 2023). the eko sensora will be tested in the emergency department. chest pain, fatigue, shortness of breath and syncope are all symptoms that could indicate a cardiac dysfunction. the hypothesis is that this device will allow us increased ability to detect valvular heart disease that is clinically significant.


Eligibility criteria:
inclusion criteria: * chief complaint of chest pain, shortness of breath, difficulty breathing, or syncope/near-syncope. * patients with chief complaint of weakness would be eligible if over the age of 50 and have a history of at least two of hypertension, bmi\>/= 30, diabetes, hyperlipidemia, atrial fibrillation, heart attack, stroke/transient ischemic attack, prior cardiac surgery or angiography exclusion criteria: * contact isolation patients * pediatric patients under the age of 18

Keywords: eko heart murmur ai machine learning heart murmur detection
effects of oral stimulation and supplemental nursing system

Conditions: Breastfeeding

Summary: this study aimed to investigate the effect of oral stimulation and a supplemental nursing system on the time to full maternal breastfeeding and sucking success in preterm infants.

this study aimed to investigate the effect of oral stimulation and a supplemental nursing system on the time to full maternal breastfeeding and sucking success in preterm infants. the sample consisted of 70 preterm babies. oral motor stimulation and a supplemental nursing system were applied to the preterm infants in the experimental group, while no intervention was applied to those in the control group.

Eligibility criteria:
inclusion criteria: * a birth weight of 1,000 gr and above, * a gestational age between 30 and 34 weeks, * no congenital anomaly, * no severe asphyxia or chronic lung disease, * spontaneous breathing, * grades iii and iv intracranial hemorrhage and no periventricular leukomalacia exclusion criteria. * congenital anomaly * grades iii and iv intracranial hemorrhage and periventricular leukomalacia

Keywords: preterm oral stimulation supplemental nursing system
postoperative muscular pain, etoims (electrical twitch obstructive intramuscular stimulation)

Conditions: Disease Status of Pancreatobiliary Tract , ( Especially Who Need to Undergo Pancreaticoduodenectomy)

Summary: pancreaticoduodenectomy is inevitably an operation requiring extensive skin and muscle incision, resulting in postoperative pain resulting in limitation of the patient's early exercise and function. etoims(electrical twitch obstructive intramuscular stimulation) is used to relieve muscle pain and relax muscles. etoims is a method to relieve pain by stimulating muscle in myofascial pain syndrome. etoims as an effective new treatment for pain after pylorus preserving pancreaticoduodenectomy.


Eligibility criteria:
inclusion criteria: * patients undergoing pancreatoduodenectomy in gangnam severance hospital, seoul, korea * patients who are able to perform daily activities before surgery and were able to walk independently. * adults over 20 exclusion criteria: * patients with history of previous open surgery * patients who are not able to exercise due to severe musculoskeletal pain except surgery-related diseases * patients who can not walk because of difficulty breathing related to myalgia * patients who can not exercise due to severe musculoskeletal pain * patients who had a limb defect before surgery and were unable to walk without assistive devices and others * pregnant / lactating mothers * patients who have cognitive impairment and can not answer the questionnaire * patients with pacemaker * patients who can not read the consent form
real-world practice patterns and outcomes of lower-risk myelodysplastic syndrome patients in japan

Conditions: Lower-risk Myelodysplastic Syndromes

Summary: the purpose of this study is to describe the treatment patterns, clinical outcomes, healthcare resource utilization (hcru) and medical costs of lower-risk myelodysplastic syndromes patients in japan.


Eligibility criteria:
inclusion criteria: * participants with at least one definitive myelodysplastic syndrome (mds) diagnosis as per the 10th revision of the international statistical classification of diseases and related health problems (mds; icd10: d46.x) between 01-may-2017 and 31-jan-2022 * participants with confirmed low-risk mds by international prognostic scoring system (ipss) or revised international prognostic scoring system (ipss-r) during baseline as follows: * record of low (0 points) or intermediate-1 (\>0 to 1 point) mds according to ipss scoring; or * record of very low (≤1.5), low (\>1.5-3), or intermediate (\>3-4.5) mds according to ipss-r scoring; or * mention of very low, low, intermediate, intermediate-1, or lower risk mds in the electronic medical records (emr) * participants with a record of a confirmed bone marrow procedure (bone marrow aspiration code d404-00 and/or bone marrow biopsy code d404-02) during baseline period exclusion criteria: * participants not meeting the inclusion criteria * participants \<18 years of age at index date * participants who have a look back period \<30 days from initial myelodysplastic syndrome diagnosis date
a study to evaluate milr1444a in the prevention of allergen-induced airway obstruction in adults with mild allergic asthma

Conditions: Allergic Asthma

Summary: this is a multicenter, randomized, double-blind, placebo-controlled study designed to demonstrate the safety and efficacy of milr1444a compared with placebo in reducing the airway reaction to an inhaled aeroallergen solution in adult patients with mild allergic asthma. the study will randomize approximately 24 patients at five study centers. in the event of patient discontinuation from the study, additional patients may be enrolled at the discretion of the sponsor.


Eligibility criteria:
inclusion criteria: * meet criteria for the diagnosis of allergic asthma * diagnosis of asthma ≥ 6 months * currently treated with only intermittent short-acting inhaled β-adrenergic agonists * body weight between 40-120 kg * normal chest x-ray within 2 years of screening exclusion criteria: * require daily controller medication for asthma * history of hypersensitivity to the study drug or to drugs with similar chemical structures or to any ingredients, including excipients of the study medication or drugs related to milr1444a (e.g., monoclonal antibodies, polyclonal gamma globulin) * documented medical history of anaphylaxis * immunotherapy currently or within the past 3 months prior to screening * lung disease other than mild allergic asthma * previous treatment with other investigational drugs within 30 days or 5 half-lives prior to the screening visit, whichever is longer * pregnant or lactating * significant concurrent medical illness other than asthma * clinically significant abnormality on ecg at the screening visit * smoked in the previous 6 months or have a history of smoking more than 10 pack-years * history of helminthic infection

Keywords: asthma
effects of plyometric exercises on static and dynamic balance of children with down,s syndrome.

Conditions: Down Syndrome

Summary: down syndrome is a condition in which a person has an extra chromosome. typically, a baby is born with 46 chromosomes. down syndrome is a genetic condition that causes mild to serious physical and developmental problems. symptoms associated with the syndrome include mental retardation, distinctive facial characteristics, and increased risk for heart defects and digestive problems, which can range from mild to severe.. early treatment programs can help improve skills. they may include speech, physical, occupational, and/or educational therapy. the aim of the the current study is to determine the effects of plyometric exercise on static and dynamic balance in children with down syndrome

this will be a randomized controlled trail. after approval from ethical committee, data will be collected from rising sun institute of special education, lahore. total sample size will be 20 and there will be two groups. group a will be given with standard physical therapy treatment twice a week for 8 weeks. while group b will be given with plyometric exercises along with standard physical therapy treatment twice a week for 8 weeks. patients will be evaluated before and after the intervention on pediatric balance scale, time up and go test, five times sit to stand. data will be analyzed on spss 26.0 and necessary analysis will be done after checking the normality of data.

Eligibility criteria:
inclusion criteria: * 6 to 12 years of age both genders will be included. * children with medical diagnosis of ds. * able to follow the command exclusion criteria: * recent injury to lower extremities. * children with cerebral palsy and other neuromuscular disease will be excluded.

Keywords: balance, dynamic, down syndrome, plyometric, static.
a study of efficacy and safety of rosnilimab in subjects with moderate to severe ulcerative colitis (rosetta)

Conditions: Ulcerative Colitis

Summary: rosetta study: this study will evaluate the safety, tolerability, and efficacy of rosnilimab in subjects with moderate to severe ulcerative colitis (uc)

this is a phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics (pk), pharmacodynamics (pd), and immunogenicity of rosnilimab in subjects with moderate to severe ulcerative colitis (uc).

Eligibility criteria:
inclusion criteria: * male or female ≥18 * participants with a clinical diagnosis of uc for prior to day 1 * subject has moderate to severe, active uc, defined as a mms ≥ 5 with an endoscopy subscore ≥2 * subject has had a surveillance colonoscopy that did not detect potential dysplasia or colon cancer performed within 1 year of day 1. * subject has a history of an inadequate response, loss of response, or intolerance to any combination of at least 2 uc therapy classes defined as, but not limited to, aminosalicylates, corticosteroids, immunomodulators, calcineurin inhibitors, or advanced uc therapies (e.g., biologics, jak inhibitors, oral s1p receptor modulators, etc.) exclusion criteria: * subject has a diagnosis of crohn's disease or indeterminate colitis. * subject has a diagnosis of fulminant colitis and/or toxic megacolon. * subject has a history of an inadequate response, loss of response, or intolerance to any combination of 3 or more advanced uc therapy classes but not limited to, 1) anti-tnf antibodies (e.g., adalimumab, golimumab, infliximab), 2) other biologics (e.g., ustekinumab, vedolizumab), 3) oral jak inhibitors (e.g., tofacitinib, upadacitinib), and 4) oral s1p receptor modulators (e.g., ozanimod). * subject has disease limited to the rectum (ulcerative proctitis) * subject has a history of colectomy (total or subtotal), ileoanal pouch, kock pouch, or ileostomy or is planning bowel surgery. * the subject had prior exposure to a pd-1 or pd-l1 agonist, antagonist, or modulator.

Keywords: rosnilimab anb030 pd-1 agonist rosetta
effectiveness of anti-hiv drugs in patients who have not received previous anti-hiv drugs during different stages of hiv infection

Conditions: HIV Infections

Summary: the purpose of this study is to compare changes in hiv levels and certain immune cells among patients at different stages of hiv infection. this study will also see how a combination of stavudine (d4t), lamivudine (3tc), indinavir (idv), and nelfinavir (nfv) affects these levels. current findings in anti-hiv drug treatment have led to a greater understanding of the background of hiv. to find the best anti-hiv treatment to eliminate all hiv viruses, cells and tissues infected with the hiv virus are examined after combination anti-hiv treatment, when the level of hiv infection is low. the eradicate study will examine the idea that hiv viruses can be eliminated at any stage of infection over time.

recent advancements in antiretroviral therapy have led to a better understanding of the natural history and immunopathogenesis of hiv-1 infection. to calculate the degree and duration of antiretroviral effect necessary to eliminate infection, characterization of residual cellular and tissue hiv reservoirs following high-level viral suppression is necessary. the eradicate study will evaluate the hypothesis that complete viral inhibition is possible, regardless of hiv disease stage, and leads to hiv eradication from tissues over time. patients are divided into 1 of 5 groups based on the stage of hiv infection. patients receive oral stavudine (d4t), lamivudine (3tc), indinavir (idv), and nelfinavir (nfv) twice daily for 24 weeks. all patients undergo basic blood sampling to follow hiv-1 rna levels and absolute t cell subset numbers daily for 5 days; then 3 times a week for 3 weeks; 2 times a week for 4 weeks; every 2 weeks for 12 weeks; and monthly thereafter for a total of 3 years. in addition, the following tissues are sampled at baseline and after 2 weeks and 6 months on therapy: 1) lymph node; 2) tonsillar; 3) perirectal lymphoid; 4) cerebrospinal fluid; 5) and semen.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * are infected with hiv and have had certain tests to indicate the stage of their disease. * are at least 18 years old. * practice birth control during the study. exclusion criteria patients will not be eligible for this study if they: * have received anti-hiv medication for more than 1 week. * have a serious aids-related infection or other illness. * require medication that interferes with the study drugs. * have had a peripheral neuropathy, a painful condition affecting the nervous system. * have been given drugs that affect the immune system within 2 weeks before study entry. * have a bleeding disorder including hemophilia. * abuse alcohol or substances. * are pregnant or breast-feeding.

Keywords: t-lymphocytes hiv-1 lymphoid tissue stavudine hiv protease inhibitors polymerase chain reaction biological markers lamivudine indinavir rna, viral genotype phenotype cytokines nelfinavir macrophages reverse transcriptase inhibitors in situ hybridization anti-hiv agents viral load cell membrane acute infection treatment naive
proof-of-concept trial of palonosetron and olanzapine without dexamethasone for the prevention of cin

Conditions: Chemotherapy-induced Nausea and Vomiting

Summary: the purpose of this study is to determine whether palonosetron and olanzapine without dexamethasone for the prevention of moderate risk chemotherapy-induced nausea and vomiting.

this study was designed to evaluate efficacy and safety of olanzapine compared with 5-hydroxytryptamine3 receptor antagonist for prevention of moderate risk chemotherapy induced nausea and vomiting.

Eligibility criteria:
inclusion criteria: * european cooperative oncology group (ecog) performance status of 0, 1, or 2 * no severe cognitive compromise * moderate risk chemotherapy induced chemotherapy induced nausea and vomiting in 1st cycle * confirmed histology exclusion criteria: * european cooperative oncology group (ecog) performance status of 3 and 4 * nausea or vomiting in the 24 hours before enrollment * history of nausea or vomiting grade 3 before previous chemotherapy * known history of central nervous system disease (e.g., brain metastases or a seizure disorder) * bowel obstruction * serum creatinine level of 2.0 mg per deciliter (177 μmol per liter) or more * aspartate or alanine aminotransferase level that was more than 3 times the upper limit of the normal range * treatment with another antipsychotic agent such as risperidone, quetiapine, clozapine, a phenothiazine, or a butyrophenone within 30 days before enrollment * treatment with another antiemetic agent before 48 hours before enrollment * uncontrolled severe infection or uncontrolled severe comorbidity * concurrent abdominal radiotherapy * known hypersensitivity to olanzapine, palonosetron * known cardiac arrhythmia, uncontrolled congestive heart failure, or acute myocardial infarction within the previous 6 month

Keywords: olanzapine chemotherapy-induced nausea and vomiting moderate risk